Natera, Inc. (NASDAQ:NTRA) Stake Lessened by Natixis Advisors LLC

Natixis Advisors LLC cut its stake in Natera, Inc. (NASDAQ:NTRA) by 2.5% in the 4th quarter, HoldingsChannel reports. The fund owned 30,264 shares of the medical research company’s stock after selling 787 shares during the period. Natixis Advisors LLC’s holdings in Natera were worth $4,791,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Principal Securities Inc. boosted its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its stake in Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 61 shares during the last quarter. Silver Oak Securities Incorporated lifted its stake in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock valued at $470,000 after purchasing an additional 89 shares during the last quarter. Blue Trust Inc. lifted its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Finally, Hanseatic Management Services Inc. lifted its stake in Natera by 12.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock valued at $158,000 after purchasing an additional 107 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. This represents a 22.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John Fesko sold 669 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40. Following the transaction, the insider now owns 114,142 shares in the company, valued at approximately $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 307,466 shares of company stock worth $49,047,655 in the last 90 days. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on NTRA. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday. BTIG Research reissued a “buy” rating on shares of Natera in a research note on Friday, February 28th. Piper Sandler increased their target price on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group upped their price target on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $178.12.

Natera Stock Up 1.0 %

NTRA stock opened at $151.15 on Friday. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a market cap of $20.43 billion, a price-to-earnings ratio of -85.88 and a beta of 1.80. The company has a 50 day moving average of $161.23 and a two-hundred day moving average of $149.50.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.